Answers are grounded in this paper and cite their sources.
Despite treatment, a considerable proportion of patients with Guillain-Barré syndrome (GBS) experience poor recovery, highlighting a therapeutic need. There is a lack of evidence that treatment timing affects recovery. This study aims to investigate the effects of intravenous immunoglobulin (IVIg) timing on disability and speed of recovery in GBS.
No takes yet. Share an insight, caveat, or question.
Min et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: